6.1(top 2%)
Impact Factor
6.5(top 2%)
extended IF
177(top 1%)
H-Index
5.8K
authors
5.3K
papers
265.7K
citations
5.8K
citing journals
114.6K
citing authors

Most Cited Articles of Molecular Cancer Therapeutics

TitleYearCitations
PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy20151.2K
Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers20171.2K
Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling20081.1K
Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity20081K
The role of autophagy in cancer: therapeutic implications2011883
Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth2011847
Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts2004769
MK-2206, an allosteric Akt inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo2010705
The role of the cyclin-dependent kinase inhibitor p21 in apoptosis2002610
Nanotechnology in cancer therapeutics: bioconjugated nanoparticles for drug delivery2006591
Antitumor activity of the glutaminase inhibitor CB-839 in triple-negative breast cancer2014573
Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma2007547
Reverse phase protein array: validation of a novel proteomic technology and utility for analysis of primary leukemia specimens and hematopoietic stem cells2006526
Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin2008525
The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo2001487
Tumor-stroma interactions in pancreatic ductal adenocarcinoma2007471
Stereospecific PARP trapping by BMN 673 and comparison with olaparib and rucaparib2014459
DZNep is a global histone methylation inhibitor that reactivates developmental genes not silenced by DNA methylation2009444
Identification and characterization of NVP-BKM120, an orally available pan-class I PI3-kinase inhibitor2012432
Pharmacokinetic-pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity2007424
Platinum neurotoxicity pharmacogenetics2009417
A modeling analysis of the effects of molecular size and binding affinity on tumor targeting2009411
Abnormal lysosomal trafficking and enhanced exosomal export of cisplatin in drug-resistant human ovarian carcinoma cells2005402
Constitutive and inducible Akt activity promotes resistance to chemotherapy, trastuzumab, or tamoxifen in breast cancer cells2002400
Discovery and development of anticancer aptamers2006394